6 results
Primary:to assess the reduction of initial study drug Cmax after administration of 20 mg study drug 10% SRF using three modified formulations as compared to the current Phase 3 formulation in healthy volunteers.Secondary:to assess the safety and…
The first objective to investigate is the pharmacokinetics of DP tobramycin using the Cyclops® at four different dosages. The other objective is the local tolerability of DP tobramycin using the Cyclops® at four different dosages.
The purpose of the study is to confirm the skin test results in patients based on results of the control population of healthy volunteers never exposed to taspoglutide or any product with a similar mechanism of action.
To determine the ratio of parent drug to metabolites in the circulation.Profiling of [14C]-etripamil metabolites in blood, urine and feces.To determine the mass balance of drug-related materials following intranasal administration.To determine the…
The main objectives are to investigate the pharmacokinetic properties of DP tobramycin via the Cyclops® at different dosages in children with CF, together with the local tolerability.
The primary objective of this study is to demonstrate the superiority of etripamil NS over placebo in reducing ventricular rate in patients with AF.